NORPLANT Drug Patent Profile

Which patents cover Norplant, and when can generic versions of Norplant launch?

Norplant is a drug marketed by Population Council and Wyeth Pharms Inc and is included in two NDAs.

The generic ingredient in NORPLANT is levonorgestrel. There are twenty drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the levonorgestrel profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Norplant

A generic version of NORPLANT was approved as levonorgestrel by NOVEL LABS INC on February 22^nd, 2013.

Summary for NORPLANT

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	112
Clinical Trials:	7
Patent Applications:	4,706
DailyMed Link:	NORPLANT at DailyMed

Recent Clinical Trials for NORPLANT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Women and Infants Hospital of Rhode Island	N/A
Society of Family Planning	Phase 4
Oregon Health and Science University	Phase 4

See all NORPLANT clinical trials

US Patents and Regulatory Information for NORPLANT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Population Council	NORPLANT	levonorgestrel	IMPLANT;IMPLANTATION	019897-001	Dec 10, 1990		DISCN	No	No
Wyeth Pharms Inc	NORPLANT SYSTEM IN PLASTIC CONTAINER	levonorgestrel	IMPLANT;IMPLANTATION	020088-001	Dec 10, 1990		DISCN	No	No

Expired US Patents for NORPLANT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Population Council	NORPLANT	levonorgestrel	IMPLANT;IMPLANTATION	019897-001	Dec 10, 1990	3,850,911
Population Council	NORPLANT	levonorgestrel	IMPLANT;IMPLANTATION	019897-001	Dec 10, 1990	3,959,322

International Patents for NORPLANT

See the table below for patents covering NORPLANT around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	120747
United Kingdom	1069842
Switzerland	417584	Verfahren zur Herstellung von Steroid-Verbindungen
Sweden	334878
Germany	1443124

Supplementary Protection Certificates for NORPLANT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1453521	39/2015	Austria		PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
1453521	122015000093	Germany		PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
1453521	132016000025143	Italy		PRODUCT NAME: LEVONORGESTREL ED ETINILESTRADIOLO(SEASONIQUE); AUTHORISATION NUMBER(S) AND DATE(S): 17/0017/15-S, 20150211;042139016, 20150414
1453521	93156	Luxembourg		PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
1453521	C 2015 029	Romania		PRODUCT NAME: LEVONORGESTREL SI ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: RO 7793/2015/001; DATE OF NATIONAL AUTHORISATION: 20150612; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): SK. 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150129

NORPLANT Market Dynamics and Financial Trajectory

Last updated: May 6, 2026

NORPLANT is a long-acting contraceptive implant product line (levonorgestrel) owned and commercialized through different rights-holders by geography, with a history anchored in the implant class and sustained demand for durable, low-maintenance contraception. Market dynamics are driven by (1) contraceptive procurement cycles and tendering, (2) regulatory lifecycle milestones for implantable levonorgestrel products, and (3) competitive substitution within long-acting reversible contraception (LARC).

What defines NORPLANT’s demand profile?

NORPLANT demand is less about “peak-season” use and more about durable contraception adoption, typical-channel penetration, and government or provider procurement. The core demand drivers are:

• Contraceptive method preference for LARC: Implants reduce adherence risk versus short-interval methods and align with public health programs focused on pregnancy prevention with low user action.
• Procurement cadence: Government tenders and public-sector supply planning determine year-to-year volume more than OTC conversion.
• Service delivery capacity: Implant insertion and removal require trained providers. Adoption rises when health systems scale trained services.
• Substitution and switching: Patients and providers can switch to alternate levonorgestrel implants or competitor brands, especially when procurement pricing, supply continuity, and labeling features change.

Commercial implication: NORPLANT’s revenue trajectory tends to follow (a) LARC adoption rates and (b) the product’s ability to stay listed, supplied, and competitively priced in each market’s procurement system.

How do supply, regulatory status, and lifecycle factors move the market?

The implant market is regulated at the product level (approval/renewal, packaging, labeling, and local pharmacovigilance obligations) and also influenced by manufacturing continuity. Key lifecycle mechanics that typically govern NORPLANT-like assets:

1. Regulatory maintenance and renewals

   • Maintaining marketing authorization supports continued procurement.
   • Label changes or manufacturing updates can affect availability and tender eligibility.

2. Manufacturing and distribution stability

   • Implants require consistent supply for scheduled insertion windows.
   • Any supply disruption can cause a “lost cohort” of insertions that may take multiple procurement cycles to recover.

3. Therapeutic class competitive displacement

   • Competitors within levonorgestrel implants or alternative contraceptive formats can displace market share through price, device convenience, and local program fit.

Commercial implication: NORPLANT revenue is exposed to both product-level regulatory continuity and program-level procurement selection behavior.

What competition patterns shape pricing power and share?

NORPLANT competes in the LARC segment where buyers compare total cost of contraception over the duration of use and service workflows. Pricing power is constrained when buyers have multiple clinically acceptable implant options.

Common competitive pressure channels:

• Public-sector tenders: Lowest evaluated price plus supply reliability often wins.
• Provider and guideline influence: Where guidelines favor specific devices or insertion kits, adoption shifts toward those brands.
• Shelf and insertion logistics: Brands with smoother supply chains and kit availability reduce stockouts and support higher effective uptake.

Commercial implication: Unless NORPLANT holds a protected listing position or has a cost advantage in a specific geography, it typically faces margin compression as the tender market attracts new supply.

Which market segments typically buy and fund NORPLANT?

NORPLANT’s market is shaped by two buyer groups:

• Public and quasi-public health programs: Ministries, national health systems, and NGO programs often purchase LARC in bulk.
• Private providers and clinics: Fertility planning services and women’s health clinics purchase via wholesalers and distributor networks.

The split affects financial trajectory:

• Public-sector share stabilizes volume but drives pricing to tender economics.
• Private-sector share can support higher net pricing but is more sensitive to availability and reimbursement policies.

What is the financial trajectory likely to look like under these dynamics?

A NORPLANT-like financial profile in mature contraception markets typically shows:

• Early-stage growth driven by adoption and market entry/listing.
• Mid-life stabilization when procurement cycles repeat and provider education scales.
• Late-life margin pressure as competitive tendering intensifies and alternatives increase.

Financial trajectory is then shaped by product and portfolio events:

• Loss of exclusivity dynamics (where applicable in specific geographies for formulation/device IP estates) tends to shift revenue from premium pricing toward parity or discounting.
• Regional regulatory and supply discontinuities can create step-changes in revenue due to insertion cohorts missing tender windows.
• Device and kit updates can affect procurement scoring and public program uptake.

How should business teams interpret NORPLANT’s revenue drivers by levers?

The revenue model for an implant brand typically maps to four measurable levers:

1. Tender/listing continuity
   • If NORPLANT stays on essential drug or contraception lists, volumes remain anchored.
2. Effective supply (no stockouts)
   • Implants require continuous availability for planned insertion.
3. Price and evaluated procurement cost
   • Tender criteria compress margins unless the brand is a cost winner.
4. Provider network readiness
   • Insertion and removal training determines real-world uptake.

Market outcome framework: what tends to happen when each lever moves?

Lever	Positive shift	Financial impact	Negative shift	Financial impact
Listing continuity	Maintains tender eligibility	Volume stability	Delisted/suspended	Revenue step-down
Supply reliability	No stockouts across cycles	Maintains insertion cohorts	Delivery delays	Missed insertions, delayed recovery
Pricing	Wins on evaluated cost	Margin resilience	Loses tender to lower-cost alternatives	Margin compression
Provider readiness	Higher insertion capacity	Share gains in LARC	Low training coverage	Slower adoption

Is NORPLANT growth tied to population growth or to contraception adoption?

For contraception implant products, revenue growth usually tracks contraception method mix more than population growth. The strongest observed correlation in LARC markets is with:

• growth in public program LARC procurement, and
• patient uptake of LARC in reproductive health settings.

This creates a financial pattern where NORPLANT can grow even without rapid population expansion, provided health system procurement and training scale.

What financial risks matter most for NORPLANT-style products?

Primary risk categories that directly affect revenue trajectory:

• Procurement concentration: A limited number of buyers can drive lumpy revenues. Losing a large buyer can create outsized downside.
• Tender price resets: Public-sector economics can reduce gross margin even when unit volume holds.
• Supply chain constraints: Manufacturing disruptions can reduce implant availability and cause multi-cycle revenue loss.
• Competitive substitution: Alternative LARC products can replace NORPLANT if they win tenders or gain clinical/program preference.

What growth levers exist in mature markets?

Even in mature contraception landscapes, revenue can increase through:

• Market share gains in specific regions via procurement wins and distributor coverage,
• Program expansion when health systems scale family planning initiatives,
• Improved service delivery that increases insertion rates and reduces discontinuation.

What does the competitive and pricing equilibrium imply for valuation?

In mature LARC markets, implant assets often trade on:

• the stability of contracts/listings,
• predictability of supply and manufacturing scaling,
• and the ability to defend cost position in tender markets.

When procurement pricing floors get pressured by additional suppliers, valuation expectations shift from revenue growth to cash flow stability.

Key Takeaways

• NORPLANT demand is driven by LARC adoption, procurement cadence, and service delivery capacity rather than short-term consumer cycles.
• Market dynamics are governed by tender/listing continuity, supply reliability, and competitive substitution within levonorgestrel implant offerings.
• Financial trajectory typically shows volume stability with margin compression risk in mature markets, punctuated by revenue step-changes when listings change or supply gaps disrupt insertion cohorts.
• The dominant revenue levers are listing continuity, effective supply, evaluated procurement cost, and provider readiness, with public-sector concentration adding lumpy revenue risk.

FAQs

1) What mostly determines NORPLANT’s unit volume each year?
Public and private procurement decisions, insertion scheduling, and whether the product remains continuously available through procurement cycles.

2) Does NORPLANT typically face strong brand-consumer pricing pressure?
Pricing pressure comes primarily from tender evaluation economics and substitution risk rather than consumer price-shopping.

3) What are the main causes of revenue step-changes for implant products?
Delisting or authorization changes in key geographies, manufacturing or distribution interruptions, and loss of major procurement contracts.

4) How does competition usually affect NORPLANT margins?
Competitor implant products can reset evaluated cost in tenders, compressing gross margins even when unit volume holds.

5) Which operational factor most affects “real” uptake?
Provider capacity for insertion and removal, because it determines how effectively sold inventory converts into completed patient use.

References

[1] World Health Organization. Contraceptive implant: WHO medical eligibility criteria for contraceptive use. WHO; relevant editions.
[2] FDA. NDA/ANDA Drug Approval Reports and Labeling Information for levonorgestrel implant comparators (product-specific pages).
[3] EMA. EPAR and assessment reports for levonorgestrel implant medicinal products and related contraceptive device guidance (product-specific).
[4] United Nations Population Fund (UNFPA). Family Planning Commodity Procurement and contraceptive market program documentation (LARC procurement context).
[5] PubMed. Review articles on LARC adoption drivers, public-sector procurement behavior, and contraceptive implant market dynamics.